Conference Coverage

Wearable devices show promise in monitoring multiple sclerosis


 

Reducing daily step count

Approached for comment, Riley M. Bove, MD, MSc, Assistant Professor, UCSF Weill Institute for Neurosciences, San Francisco, said that the study is “very interesting and in line with what has been previously published.”

She pointed to a recent study that she co-authored, in which remote monitoring via a continuous step counter revealed that a decreasing average daily step count was associated with the worsening of standard ambulatory measures.

“There are nice benefits of an integrated platform” such as what was used in the current study, Dr. Bove noted, adding that it is “even better if it can also send the data to clinicians.”

The ALAMEDA project has received funding from the European Union’s Horizon 2020 research and innovation program. No relevant financial relationships declared.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

DMT discontinuation trial halted; MS returned in 17.8%
ICYMI Multiple Sclerosis
Obesity linked to multiple ills in MS study
ICYMI Multiple Sclerosis
Ocrelizumab benefit confirmed in older patients with MS
ICYMI Multiple Sclerosis
AI tool reveals MS drug interactions, offers safer options
ICYMI Multiple Sclerosis
Next up in MS trials: More insight into progressive disease
ICYMI Multiple Sclerosis
‘We’re halfway home’: UCSF’s Dr. Stephen Hauser sketches MS future
ICYMI Multiple Sclerosis
MS-tailored weight loss program achieves meaningful results
ICYMI Multiple Sclerosis
Stem cell transplants in early MS: Who benefits most?
ICYMI Multiple Sclerosis
EBV and MS: Just how deep is the link?
ICYMI Multiple Sclerosis
NMO: Study says double diagnoses with MS are common
ICYMI Multiple Sclerosis